Cancer and immune studies point to the neighbourhood, not the single cell

Age reshapes the head and neck tumour neighbourhood

In a preprint posted to bioRxiv, researchers studied HPV-negative head and neck cancer. Age-associated differences in tumour composition were driven by selective shifts in cell type abundance and organisation, rather than by widespread transcriptional rewiring within cells. That distinction matters for how the result is read: the aged tumour looks different mainly because the mix of cells and the way they are arranged changes, not because every cell type rewrites its program. m:…6132

The preprint identifies an age-enriched cellular community made up of basal-like squamous epithelial states, matrix-associated myofibroblast-like cancer-associated fibroblasts and FOLR2-positive macrophages. It also links Midkine, known as MDK, a tumour-derived signal, to stromal remodelling, immunosuppression and invasive epithelial programs in aged patients. Taken together, those findings point to a community-level explanation for age-related progression and to MDK as a candidate target for age-stratified therapy, rather than to a single malignant cell type acting alone. m:…6132

A breast cancer target and a quieter immune signature

In a second preprint posted to bioRxiv, researchers examined TROP2 in triple-negative breast cancer through its gene TACSTD2. TACSTD2 expression did not differ significantly by race or African genetic ancestry. That result separates the target itself from ancestry as an explanation for differences in expression, which matters for who might be considered for TROP2-targeted approaches. m:…0118

What did vary with TACSTD2 was the immune context around the tumour. Higher TACSTD2 expression was associated with lower CD8A, GZMB and cytotoxic scores, independent of epithelial cell content. The association with reduced cytotoxic immune markers was stronger than the association observed for EPCAM or KRT8. The pattern suggests that tumours with more of this target tend to sit in a quieter cytotoxic immune neighbourhood, a context that could shape how immunotherapy is evaluated, even though the preprint does not show that changing TROP2 changes the immune response. m:…0118

Resetting a B cell repertoire in autoimmune disease

A third preprint, also posted to bioRxiv, turns from cancer to autoimmune disease, but keeps the same community logic: outcome depends on which immune cells remain, not only on which single molecule is blocked. The study covers patients with systemic lupus, idiopathic inflammatory myopathies and systemic sclerosis, . CD19-CAR T-cell therapy depleted EBV-positive B cells in those patients. The EBV-positive B cells in autoimmune disease were predominantly Latency III and resistant to anti-CD20 and anti-CD19 antibodies, which helps explain why antibody depletion alone may leave a reservoir behind. m:…5787

After CAR T-cell therapy, the B-cell repertoire reset toward a naive state, predominantly IgM-positive with minimal somatic hypermutation. The authors present the EBV-positive B-cell reservoir as a target for CAR T-cell therapy and as a basis for patient stratification in trial design. The result is a repertoire story: removing a persistent population and allowing a naive repertoire to re-emerge, rather than suppressing one pathway. m:…5787

Rewiring skin immunity without losing defence

In a fourth preprint posted to bioRxiv, on chronic skin inflammation rather than cancer, topical JAK1 and JAK2 inhibition selectively suppressed pathogenic CD8 T cells and interferon-gamma production. The same treatment shifted Th2-polarised CD4 T cells toward a Th17 phenotype, preserving type 3 immunity. That combination is the point of interest: pathogenic type 1 and type 2 activity falls while antimicrobial type 3 responses are retained, so tissue repair does not come at the cost of losing host defence entirely. m:…2722

Adding IL-17A blockade to JAK1 and JAK2 inhibition improved tissue homeostasis further by targeting residual type 3-driven pathology. The authors present the result as a mechanistic rationale for combination therapy in chronic inflammatory disease: resolve residual pathology while maintaining host defence. Read alongside the cancer preprints, the skin study reinforces the shared theme. Immune outcomes depend on how a whole community of T cells is rewired, and on which parts of that community are preserved, not only on whether one signal is switched off. m:…2722

What remains open

All four studies are preprints, so none of the findings has yet passed through peer review, and none directly demonstrates a clinical benefit in a randomised comparison. The head and neck study does not show that blocking MDK improves outcomes in aged patients. The breast cancer study shows an association between TACSTD2 and cytotoxic markers, not proof that TROP2-targeted therapy will change that immune context. The CAR T study reports a repertoire reset in autoimmune disease, and the skin study reports tissue effects without long-term safety data for the combination. The useful next step in each case is the same: test whether changing the community, rather than describing it, changes outcomes for patients. m:…6132 m:…0118 m:…5787 m:…2722